Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland

Abstract

A group of 98 families were analyzed for CYP1B1 gene 355T/T homozygous genotype frequency because of prostate cancer history. Molecular investigations were performed using the restriction fragment length polymorphism-PCR method. 355T/T genotype was detected in 14 of the 98 prostate cancer patients (14.3%). Among them, it was found in one man (7.1%) from a family suspected of hereditary prostate cancer (his age at prostate cancer diagnosis was 57 years) and in 13 men (92.9%) originating from families that did not strictly fulfill hereditary prostate cancer criteria (the median age at prostate cancer diagnosis was 60.1 years). Among 14 355T/T genotype-positive families, in 10 (71.4%) other types of cancers, for example, breast, uterus, stomach, colon, ovary, lung, larynx, bladder, pancreas and melanoma other than prostate cancer, were present, and in four (28.6%) only one cancer type, that is, prostate cancer, occurred. In the Polish population, the CYP1B1 355T/T genotype seems to be associated with prostate cancer; the frequency of this genotype was 5.9% higher in prostate cancer patients than in the general population (8.4%). However, it is not associated with prostate cancer family history.

Concomitance of oncogenic HPV types, CHEK2 gene mutations, and CYP1B1 gene polymorphism as an increased risk factor for malignancy

“…In turn, studies of the 355T/T variant in male subjects with positive familial history towards prostate cancer 14.3% revealed the variant to have occurred in 14 out of 98 examined subjects in the study group, which gave a prevalence level of 14.3%. Among the identified carriers of the CYP1B1 gene 355T/T variant, the majority (71.4%) were patients with family–confirmed neoplasms of other organs: breast, uterus, stomach, colon, ovaries, lungs, larynx, urinary bladder, pancreas, and patients with melanoma [19]. The 355T/T polymorphism – Ala119Ser – in codon 119 is located at an important region of the gene, namely at the site of SRS1 substrate identification [20].…”